AEON fails another migraine trial, shares halve as company reviews options
AEON Biopharma said its botulinum toxin treatment candidate failed a Phase 2 migraine study at the planned interim analysis. The company’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
